During the past decade, Raleigh Pediatric Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Raleigh Pediatric Associates" are "Respiratory Syncytial Virus Infections" (2 trials) and "Asthma" (1 trials). Many other conditions were trialed in "Raleigh Pediatric Associates" in a lesser frequency.

Most popular intervention types in "Raleigh Pediatric Associates" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (1 trials), "levalbuterol tartrate MDI" (1 trials), "motavizumab (MEDI-524)" (1 trials), "palivizumab" (1 trials) and "racemic albuterol MDI" (1 trials). Other intervention names were less common.

The vast majority of trials in "Raleigh Pediatric Associates" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Raleigh Pediatric Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Raleigh Pediatric Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Raleigh Pediatric Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".